Oncology: Surgical Ablation Devices Market
Oncology: Surgical Ablation Devices Market
$4,750.00
Valued at approximately $380m in 2017, the Surgical Ablation Devices Market for Oncology is expanding at a double-digit rate, driven by the increasing global prevalence of cancer and the growing demand for better healthcare in emerging markets.
Publisher: Meddevicetracker
- Description
- Contents
OVERVIEW
Valued at approximately $380m in 2017, the Surgical Ablation Devices Market for Oncology is expanding at a double-digit rate, driven by the increasing global prevalence of cancer and the growing demand for better healthcare in emerging markets. New and emerging technologies for cancer ablation, such as laser interstitial thermotherapy/LiTT (although arising from a very small base), high-intensity focused ultrasound (HIFU), and irreversible electroporation (IRE) are expected to grow at the fastest rates during the forecast period.
The major driver pushing market growth is the increasing incidence of cancer. The rise in the global cancer incidence is a combined result of the expanding geriatric demographic, population growth, and an increased prevalence of cancer risk factors (such as obesity and type II diabetes). In addition, improved diagnostic techniques are leading to an increase in the number of cancers detected at an early stage, fueling growth for less invasive, tissue-sparing techniques. A major factor currently limiting market growth is the lack of long-term efficacy and value-based outcomes data on various ablation technologies.
This medical market and technology report provides an overview and in-depth market analysis of ablation devices used in the treatment of cancer, including 6 core ablation segments: energy-based systems for heat-based ablation including HIFU, microwave ablation (MWA), and radiofrequency ablation (RFA), cryoablation, and IRE. Emerging technologies, such as LiTT, are also profiled.
The report provides the following information:
- An overview of cancers in which ablation is used as a treatment tool, either as an approved or as an investigational treatment
- Key statistics on selected cancers in major regions in the world
- Ablation product portfolios offered by manufacturers
- Insight into developing and potentially disruptive ablation technologies
- In-depth market and competitive analysis
Markets covered by this analysis include the US, Japan, the five major EU markets (France, Germany, Italy, Spain, and the UK), and the Rest of World (RoW) markets, which includes all other countries.
CONTENTS
Executive Summary………………………………………………………………………………………………….. ES-1
i. Cancer overview…………………………………………………………………………………………………..ES-1
ii. Devices market……………………………………………………………………………………………………ES-1
a. Market drivers and limiters……………………………………………………………………….ES-3
b. Device segment highlights – MW ablation leads but newer technologies fuel growth……………………………………………………………………………….ES-4
c. Technology trends – new ablation technologies set to make cancer breakthroughs in next five years………………………………………………….ES-5
d. Market leaders – Medtronic leads, but competition is fierce ………………………..ES-5
e. Competitive strategies – specific cancer indications could give the edge………..ES-5
f. Emerging competition – Asian manufacturers break into market…………………..ES-5
iii. Methodology……………………………………………………………………………………………………..ES-6
iv. Bibliography ………………………………………………………………………………………………………ES-8
Exhibit ES-1 Cancer ablation devices, global market forecast ($m), 2017-22 ……………………………..ES-2
Exhibit ES-2: Cancer ablation devices market, estimated sales ($m) by country/region, 2017 ……..ES-3
Exhibit ES-3: Drivers and limiters of growth – cancer ablation devices………………………………………ES-4
1. Overview of Selected Cancers and Treatment ………………………………………………………………1-1
1.1 Brain cancer ……………………………………………………………………………………………………… 1-1
1.1.1 Treatment options………………………………………………………………………………. 1-2
1.2 Breast cancer ……………………………………………………………………………………………………. 1-2
1.2.1 Treatment options………………………………………………………………………………. 1-3
1.3 Colorectal cancer ………………………………………………………………………………………………. 1-4
1.3.1 Treatment options………………………………………………………………………………. 1-5
1.4 Kidney cancer……………………………………………………………………………………………………. 1-5
1.4.1 Treatment options………………………………………………………………………………. 1-5
1.5 Liver cancer………………………………………………………………………………………………………. 1-6
1.5.1 Treatment options………………………………………………………………………………. 1-6
1.6 Lung cancer………………………………………………………………………………………………………. 1-8
1.6.1 Treatment options………………………………………………………………………………. 1-8
1.7 Pancreatic cancer………………………………………………………………………………………………. 1-9
1.7.1 Treatment options…………………………………………………………………………….. 1-10
1.8 Prostate cancer……………………………………………………………………………………………….. 1-11
1.8.1 Treatment options…………………………………………………………………………….. 1-11
1.9 Bibliography ……………………………………………………………………………………………………. 1-14
2. Ablation Therapy Technologies………………………………………………………………………………….2-1
2.1 Cryoablation……………………………………………………………………………………………………… 2-2
2.1.1 Kidney cancer……………………………………………………………………………………… 2-4
2.1.2 Liver cancer………………………………………………………………………………………… 2-5
2.1.3 Lung cancer………………………………………………………………………………………… 2-6
2.1.4 Prostate cancer…………………………………………………………………………………… 2-8
2.1.5 Breast cancer ……………………………………………………………………………………… 2-9
2.2 Selected cryoablation products…………………………………………………………………………. 2-11
2.2.1 CSA Medical ……………………………………………………………………………………… 2-11
2.2.2 Galil Medical/BTG plc…………………………………………………………………………. 2-12
2.2.3 Endocare/HealthTronics…………………………………………………………………….. 2-13
2.2.4 IceCure Medical ………………………………………………………………………………… 2-14
2.2.5 Sanarus Technologies ………………………………………………………………………… 2-14
2.3 High-intensity focused ultrasound (HIFU)……………………………………………………………. 2-15
2.3.1 Focal HIFU………………………………………………………………………………………… 2-17
2.3.2 FDA approval of HIFU…………………………………………………………………………. 2-19
2.3.3 Survey of urologists/HIFU use……………………………………………………………… 2-20
2.4 Selected HIFU products…………………………………………………………………………………….. 2-21
2.4.1 Chongqing Haifu Medical Technology Co. Ltd ……………………………………….. 2-21
2.4.2 EDAP TMS…………………………………………………………………………………………. 2-21
2.4.3 Profound Medical ……………………………………………………………………………… 2-21
2.4.4 SonaCare Medical ……………………………………………………………………………… 2-23
2.4.5 Emerging technologies……………………………………………………………………….. 2-25
2.5 Laser interstitial thermal therapy (LiTT) ……………………………………………………………… 2-26
2.5.1 Brain cancer ……………………………………………………………………………………… 2-26
2.5.2 Breast cancer ……………………………………………………………………………………. 2-29
2.5.3 Prostate cancer…………………………………………………………………………………. 2-30
2.6 Selected LITT products……………………………………………………………………………………… 2-31
2.6.1 Medtronic ………………………………………………………………………………………… 2-31
2.6.2 Monteris Medical………………………………………………………………………………. 2-32
2.6.3 Novian Health …………………………………………………………………………………… 2-33
2.6.4 Emerging technologies……………………………………………………………………….. 2-33
2.7 Microwave ablation …………………………………………………………………………………………. 2-33
2.7.1 Kidney cancer……………………………………………………………………………………. 2-37
2.7.2 Liver cancer………………………………………………………………………………………. 2-38
2.7.3 Lung cancer………………………………………………………………………………………. 2-39
2.7.4 Other applications……………………………………………………………………………… 2-41
2.8 Selected MWA products…………………………………………………………………………………… 2-41
2.8.1 Alfresa Pharma Corp………………………………………………………………………….. 2-43
2.8.2 AngioDynamics …………………………………………………………………………………. 2-43
2.8.3 Biomedical srl……………………………………………………………………………………. 2-43
2.8.4 ECO Medical……………………………………………………………………………………… 2-44
2.8.5 Ethicon …………………………………………………………………………………………….. 2-44
2.8.6 HS Hospital Service SpA ……………………………………………………………………… 2-46
2.8.7 Kang-Yu Medical ……………………………………………………………………………….. 2-47
2.8.8 Medtronic ………………………………………………………………………………………… 2-47
2.8.9 MedWaves……………………………………………………………………………………….. 2-48
2.8.10 Perseon/MedLink…………………………………………………………………………….. 2-49
2.8.11 Emerging technologies……………………………………………………………………… 2-49
2.9 Radiofrequency ablation…………………………………………………………………………………… 2-50
2.9.1 Liver tumors……………………………………………………………………………………… 2-51
2.9.2 Lung tumors……………………………………………………………………………………… 2-53
2.9.3 Kidney tumors…………………………………………………………………………………… 2-54
2.9.4 Pancreatic cancer………………………………………………………………………………. 2-55
2.10 Selected RFA products……………………………………………………………………………………. 2-56
2.10.1 AngioDynamics ……………………………………………………………………………….. 2-57
2.10.2 Boston Scientific………………………………………………………………………………. 2-57
2.10.3 HS Hospital Service SpA ……………………………………………………………………. 2-58
2.10.4 Olympus Medical …………………………………………………………………………….. 2-58
2.10.5 Medtronic ………………………………………………………………………………………. 2-58
2.10.6 RF Medical………………………………………………………………………………………. 2-59
2.10.7 STARmed (Korea)…………………………………………………………………………….. 2-59
2.10.8 Emerging technologies…………………………………………………………………….. 2-59
2.11 Non-thermal ablation …………………………………………………………………………………….. 2-60
2.11.1 Irreversible electroporation (IRE) ………………………………………………………. 2-60
2.11.2 Liver cancer…………………………………………………………………………………….. 2-61
2.11.3 Pancreatic cancer…………………………………………………………………………….. 2-62
2.11.4 Prostate cancer……………………………………………………………………………….. 2-64
2.12 Other emerging technologies………………………………………………………………………….. 2-64
2.13 Bibliography ………………………………………………………………………………………………….. 2-66
Exhibit 2-1: Advantages/disadvantages of cryoablation ………………………………………………………….. 2-3
Exhibit 2-2: Advantages/disadvantages of cryotherapy for kidney cancer …………………………………. 2-5
Exhibit 2-3: Advantages/disadvantages of cryotherapy for liver cancer…………………………………….. 2-6
Exhibit 2-4: Advantages/disadvantages of cryotherapy for lung cancer…………………………………….. 2-7
Exhibit 2-5: Advantages/disadvantages of cryotherapy for prostate cancer ………………………………. 2-9
Exhibit 2-6: Advantages/disadvantages of cryotherapy for breast cancer………………………………… 2-11
Exhibit 2-7: Selected commercially-available cryoablation products……………………………………….. 2-11
Exhibit 2-8: HIFU for prostate cancer via the transrectal approach …………………………………………. 2-16
Exhibit 2-9: Advantages/disadvantages of HIFU for prostate cancer……………………………………….. 2-17
Exhibit 2-10: Advantages/disadvantages of LiTT for brain cancer……………………………………………. 2-29
Exhibit 2-11: Advantages/disadvantages of LITT for breast cancer………………………………………….. 2-30
Exhibit 2-12: MWA vs RFA ablation zone control and technique …………………………………………….. 2-34
Exhibit 2-13: Advantages/disadvantages of MWA ………………………………………………………………… 2-36
Exhibit 2-14: Advantages/disadvantages of MWA for kidney cancer……………………………………….. 2-37
Exhibit 2-15: Advantages/disadvantages of MWA for liver cancer ………………………………………….. 2-39
Exhibit 2-16: Advantages/disadvantages of MWA for lung cancer ………………………………………….. 2-41
Exhibit 2-17: Selected commercially available MWA systems…………………………………………………. 2-42
Exhibit 2-18: Advantages/disadvantages of RFA …………………………………………………………………… 2-51
Exhibit 2-19: Advantages/disadvantages of RFA for liver cancer…………………………………………….. 2-52
Exhibit 2-20: Advantages/disadvantages of RFA for lung cancer …………………………………………….. 2-54
Exhibit 2-21: Advantages/disadvantages of RFA for kidney cancer………………………………………….. 2-55
Exhibit 2-22: Advantages/disadvantages of RFA for pancreatic cancer……………………………………. 2-56
Exhibit 2-23: Selected RFA products……………………………………………………………………………………. 2-56
Exhibit 2-24: Advantages/disadvantages of IRE…………………………………………………………………….. 2-61
3. Oncology: Surgical Ablation Devices Market…………………………………………………………………3-1
3.1 Market forecast: global………………………………………………………………………………………. 3-1
3.2 Market forecast: combined, by country/region …………………………………………………….. 3-3
3.3 The US market…………………………………………………………………………………………………… 3-6
3.3.1 Market forecast: cryoablation ………………………………………………………………. 3-6
3.3.2 Market forecast: high-intensity focused ultrasound (HIFU)………………………. 3-6
3.3.3 Market forecast: irreversible electroporation (IRE) …………………………………. 3-6
3.3.4 Market forecast: laser interstitial thermotherapy (LiTT)…………………………… 3-6
3.3.5 Market forecast: microwave ablation (MWA)…………………………………………. 3-7
3.3.6 Market forecast: radiofrequency ablation (RFA)……………………………………… 3-7
3.3.7 Procedure volumes forecast: US……………………………………………………………. 3-8
3.3.8 Reimbursement: US …………………………………………………………………………… 3-10
3.4 The five major EU markets (5EU)……………………………………………………………………….. 3-11
3.4.1 Market forecast: cryoablation …………………………………………………………….. 3-13
3.4.2 Market forecast: HIFU………………………………………………………………………… 3-13
3.4.3 Market forecast: IRE ………………………………………………………………………….. 3-13
3.4.4 Market forecast: LiTT…………………………………………………………………………. 3-13
3.4.5 Market forecast: MWA ………………………………………………………………………. 3-13
3.4.6 Market forecast: RFA …………………………………………………………………………. 3-13
3.4.7 Procedure volumes forecast: 5EU………………………………………………………… 3-15
3.5 The market in Japan…………………………………………………………………………………………. 3-17
3.5.1 Market forecast: cryoablation …………………………………………………………….. 3-17
3.5.2 Market forecast: HIFU………………………………………………………………………… 3-18
3.5.3 Market forecast: IRE ………………………………………………………………………….. 3-18
3.5.4 Market forecast: LiTT…………………………………………………………………………. 3-18
3.5.5 Market forecast: MWA ………………………………………………………………………. 3-18
3.5.6 Market forecast: RFA …………………………………………………………………………. 3-18
3.5.7 Procedure volumes forecast: Japan……………………………………………………… 3-20
3.6 The RoW market ……………………………………………………………………………………………… 3-22
3.6.1 Market forecast: cryoablation …………………………………………………………….. 3-23
3.6.2 Market forecast: HIFU………………………………………………………………………… 3-23
3.6.3 Market forecast: IRE ………………………………………………………………………….. 3-23
3.6.4 Market forecast: LiTT…………………………………………………………………………. 3-23
3.6.5 Market forecast: MWA ………………………………………………………………………. 3-23
3.6.6 Market forecast: RFA …………………………………………………………………………. 3-23
3.7 Market drivers…………………………………………………………………………………………………. 3-25
3.8 Market limiters………………………………………………………………………………………………… 3-26
3.9 Technology trends …………………………………………………………………………………………… 3-27
3.9.1 Image-guided technologies and precise control…………………………………….. 3-27
3.9.2 RFA vs MWA……………………………………………………………………………………… 3-27
3.9.3 HIFU emerges as the dominant treatment for prostate cancer……………….. 3-28
3.9.4 Cryoablation set to make its mark in breast cancer……………………………….. 3-28
3.9.5 LiTT’s application in brain cancer is still investigational ………………………….. 3-29
3.9.6 IRE seeks clinical utility in pancreatic cancer…………………………………………. 3-29
3.10 Global competitors: market share……………………………………………………………………. 3-30
3.11 Competitive analysis: cryoablation…………………………………………………………………… 3-31
3.11.1 Global market share…………………………………………………………………………. 3-31
3.11.2 US market share………………………………………………………………………………. 3-32
3.11.3 5EU market share ……………………………………………………………………………. 3-32
3.11.4 Japan market share………………………………………………………………………….. 3-33
3.11.5 RoW market share …………………………………………………………………………… 3-33
3.12 Competitive analysis: HIFU ……………………………………………………………………………… 3-34
3.12.1 Global market share…………………………………………………………………………. 3-34
3.12.2 US market share………………………………………………………………………………. 3-35
3.12.3 5EU market share ……………………………………………………………………………. 3-36
3.12.4 Japan market share………………………………………………………………………….. 3-36
3.12.5 RoW market share …………………………………………………………………………… 3-37
3.13 Competitive analysis: IRE ………………………………………………………………………………… 3-37
3.14 Competitive analysis: LiTT……………………………………………………………………………….. 3-37
3.15 Competitive analysis: MWA…………………………………………………………………………….. 3-38
3.15.1 Global market share…………………………………………………………………………. 3-38
3.15.2 US market share………………………………………………………………………………. 3-39
3.15.3 5EU market share ……………………………………………………………………………. 3-40
3.15.4 Japan market share………………………………………………………………………….. 3-40
3.15.5 RoW market share …………………………………………………………………………… 3-41
3.16 Competitive analysis: RFA……………………………………………………………………………….. 3-42
3.16.1 Global market share…………………………………………………………………………. 3-42
3.16.2 US market share………………………………………………………………………………. 3-43
3.16.3 5EU market share ……………………………………………………………………………. 3-43
3.16.4 Japan market share………………………………………………………………………….. 3-44
3.16.5 RoW market share …………………………………………………………………………… 3-45
3.17 Competitive strategies……………………………………………………………………………………. 3-45
3.17.1 Specific approvals for cancer treatment……………………………………………… 3-45
3.17.2 Investment in new technology ………………………………………………………….. 3-46
3.17.3 Acquisition of ablation technologies ………………………………………………….. 3-46
3.17.4 Overhaul of product mix…………………………………………………………………… 3-47
3.18 Emerging competition…………………………………………………………………………………….. 3-47
3.18.1 Competition from Asia……………………………………………………………………… 3-47
3.18.2 Disruptive technology………………………………………………………………………. 3-47
3.19 Bibliography ………………………………………………………………………………………………….. 3-48
3.20 Appendix ………………………………………………………………………………………………………. 3-50
3.20.1 Prostate cancer ablation survey ………………………………………………………… 3-50
Exhibit 3-1: Cancer ablation devices, global market forecast ($m), 2017-22………………………………. 3-2
Exhibit 3-2: Cancer ablation devices market, estimated sales ($m) by country/region, 2017……….. 3-4
Exhibit 3-3: Cancer ablation devices market, estimated sales ($m) by country/region, 2017……….. 3-5
Exhibit 3-4: US cancer ablation devices market forecast ($m), by product segment, 2017-22 ……… 3-7
Exhibit 3-5: US cancer ablation, procedure volumes forecast, 2017-22……………………………………… 3-9
Exhibit 3-6: 5EU cancer ablation devices market forecast ($m), by product segment, 2017-22 ….. 3-14
Exhibit 3-7: 5EU cancer ablation, procedure volumes forecast (000s), 2017-22 ……………………….. 3-16
Exhibit 3-8: Japan cancer ablation devices market forecast ($m), by product segment, 2017-22… 3-19
Exhibit 3-9: Japan cancer ablation, procedure volumes forecast (000s), 2017-22……………………… 3-21
Exhibit 3-10: RoW cancer ablation devices market forecast ($m), by product segment, 2017-22.. 3-24
Exhibit 3-11: Global cancer cryoablation devices market, share by supplier, 2017 ……………………. 3-32
Exhibit 3-12: US cancer cryoablation devices market, share by supplier, 2017 …………………………. 3-32
Exhibit 3-13: 5EU cancer cryoablation devices market, share by supplier, 2017……………………….. 3-33
Exhibit 3-14: Japan cancer cryoablation devices market, share by supplier, 2017 …………………….. 3-33
Exhibit 3-15: RoW cancer cryoablation devices market, share by supplier, 2017………………………. 3-34
Exhibit 3-16: Global cancer HIFU devices market, share by supplier, 2017 ………………………………. 3-35
Exhibit 3-17: US cancer HIFU devices market, share by supplier, 2017 ……………………………………. 3-36
Exhibit 3-18: 5EU cancer HIFU devices market, share by supplier, 2017 ………………………………….. 3-36
Exhibit 3-19: Japan cancer HIFU devices market, share by supplier, 2017………………………………… 3-37
Exhibit 3-20: Global cancer microwave ablation devices market, share by supplier, 2017 …………. 3-39
Exhibit 3-21: US cancer MW ablation devices market, share by supplier, 2017 ………………………… 3-39
Exhibit 3-22: 5EU cancer MW ablation devices market, share by supplier, 2017 ………………………. 3-40
Exhibit 3-23: Japan cancer MW ablation devices market, share by supplier, 2017 ……………………. 3-41
Exhibit 3-24: RoW cancer MW ablation devices market, share by supplier, 2017……………………… 3-41
Exhibit 3-25: Global cancer radiofrequency ablation devices market, share by supplier, 2017 …… 3-42
Exhibit 3-26: US cancer RF ablation devices market, share by supplier, 2017 …………………………… 3-43
Exhibit 3-27: 5EU cancer RF ablation devices market, share by supplier, 2017 …………………………. 3-44
Exhibit 3-28: Japan cancer RF ablation devices market, share by supplier, 2017 ………………………. 3-44
Exhibit 3-29: RoW cancer RF ablation devices market, share by supplier, 2017………………………… 3-45
Appendix A: company listing
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Pharma’s New R&D Models: Federating Innovation 
Sign up to the